Allelic and genotypic frequencies in the male bladder cancer patient and male control groups
| Polymorphism | Normal (%) | Bladder cancer (%) | Significance | |
|---|---|---|---|---|
| CCR5Δ32 | ||||
| Number of samples | 148 | 68 | ||
| Wild/wild | 127 (85.8) | 58 (85.3) | p = 0.919 | NO |
| Wild/mutated | 21 (14.2) | 10 (14.7) | df = 2 | |
| Mutated/mutated | 0 | 0 | ||
| Allele frequency | 0.0700 | 0.0735 | p = 0.923 | NO |
| Hardy–Weinberg | YES | YES | df = 1 | |
| CXCL12 | ||||
| Number of samples | 148 | 68 | ||
| Wild/wild | 67 (45.3) | 31 (45.5) | p = 0.983 | NO |
| Wild/mutated | 71 (48) | 32 (47.05) | df = 2 | |
| Mutated/mutated | 10 (9.7) | 5 (7.35) | ||
| Allele frequency | 0.3074 | 0.3088 | p = 0.976 | NO |
| Hardy–Weinberg | YES | YES | df = 1 | |
| CCR2-64I | ||||
| Number of samples | 148 | 68 | ||
| Wild/wild | 115 (77.7) | 51 (75) | p = 0.324 | NO |
| Wild/mutated | 33 (22.3) | 16 (23.5) | df = 2 | |
| Mutated/mutated | 0 (0) | 1 (1.5) | ||
| Allele frequency | 0.1115 | 0.1324 | p = 0.532 | NO |
| Hardy–Weinberg | YES | YES | df = 1 | |
| CCR5 59029 G-A | ||||
| Number of samples | 126 | 68 | ||
| Wild/wild | 34 (27) | 11 (16.1) | p = 0.130 | NO |
| Wild/mutated | 55 (43.7) | 39 (57.4) | df = 2 | |
| Mutated/mutated | 37 (29.3) | 18 (26.5) | ||
| Allele frequency | 0.5119 | 0.5515 | p = 0.456 | NO |
| Hardy–Weinberg | YES | YES | df = 1 | |